First AI-EKG/ECG Device
PhysioSign's AI-EKG/ECG is the first EKG/ECG device to automatically diagnose coronary artery disease (CAD) and other heart diseases.  A breakthrough for patients, clinicians, and healthcare costs!  Download Executive Summary here.  Please see our five slide deck here.  Please see CAD diagnosis here.

Breaking News: PhysioSign's AI-EKG/ECG can detect malignant arrhythmias! See Presentation Here

Home     People     History     Articles    Clinic     IP     Investors   Presentations   Contact

________________________________________________________________________

   How It Works
PQRST Waveform
Above is the well-known PQRST ECG waveform for which Einthoven won a Nobel Prize in 1924.  Unfortunately, the PQRST waveform reveals little information about the internal structures of the heart, which is critical to disease diagnosis.

PhysioSign's breakthrough SAAH technology detects subwaveforms within the PQRST waveform enabling disease diagnosis.
SAAH waveform
Above is the SAAH ECG waveform showing subwaveforms, including subwaveforms a, b, c, d, and e within the PR Interval. 

SAAH structures

The image above shows the internal structures of the heart corresponding to the SAAH subwaveforms a, b, c, d, and e.  

Using AI, PhysioSign's AI-EKG-ECG device compares the subwaveforms of the ECG signal of a patient to its database of normal and abnormal subwaveforms gathered from more than 1 million patient and animal studies.  From this comparison, PhysioSign's AI-EKG-ECG device can now diagnose diseases like CAD noninvasively.  Please view PhysioSign's video on SAAH technology here.

_______________________________________________________

What This Means

For Patients: Heart diseases like coronary artery disease will be detected sooner, testing will be more comfortable since ECG is noninvasive, and lives will be saved.

For Clinicians: Takes the guesswork out of reading the PQRST waveform, saves time, and improves patient outcomes.

For Healthcare Costs: Reduced by, at least, a factor of 10 by moving disease diagnosis from an invasive procedure to a noninvasive procedure.  

_______________________________________________________

Peer Reviewed


PhysioSign's AI-EKG-ECG device has been validated in numerous peer reviewed journal articles.  See some of these papers here.

_______________________________________________________

In The Clinic In China


PhysioSign has sold more than 135 AI-EKG-ECG devices and is generating even more data.  See video of ECG room and see video of PhysioSign's AI-EKG/ECG in use.  See more photos.

_______________________________________________________

Intellectual Property


PhysioSign's Intellectual Property includes its one of a kind patient and animal study database, trade secrets, and patents.  Eight of PhysioSign's U.S. patents can be viewed here.

_______________________________________________________

Market Opportunity



In 2017, the worldwide ECG Device Market was estimated to be $3.95 Billion in 2017 and is estimated to grow to $6.79 Billion by 2026.  The total worldwide Heart Attack Diagnostic Market is expected to exceed $15.4 Billion by 2024.  The device has been developed in stealth mode and is only offered for sale in China.  It has already generated revenue there with negotiations underway for more than $40 million in sales.  With additional investment, the market opportunity for PhysioSign's AI-EKG-ECG device globally is enormous.

_______________________________________________________

Vision

PhysioSign's AI-EKG-ECG device is just the beginning of the new technology developed by the PhysioSign Team.  Above is the EPCG waveform also invented by the PhysioSign Team.  Beyond use as a clinical ECG, the technology can be used in a number of other important settings.  For example, an invasive version of the technology can be used during surgeries (e.g., during A-fib ablation) to guide the surgeon.  The technology can also be used to improve and speed development of heart drugs.  The efficacy of any new heart drug can be determined more objectively using this technology.

The goal of the company is to become the leader in EKG/ECG technology globally and to continue to advance the technology. 



_______________________________________________________